

MTN-007 Study Specific Procedures Manual

Table of Contents

Section 1. Introduction

1.1	Sources of Procedural Information.....	1-1
1.2	Investigator Responsibilities	1-1
1.3	Study Activation Process.....	1-2
1.4	IRB/EC Submissions.....	1-3

Section 2. Protocol

Section 3. Documentation Requirements

3.1	Essential Documents	3-1
3.2	Participant Case History Documentation	3-2
	3.2.1 Case History Contents.....	3-2
	3.2.2 Concept of Source Data and Source Documentation	3-2
	3.2.3 Document Organization	3-5
3.3	Study Product Accountability, Chain of Custody, and Dispensing Documentation	3-7
3.4	Record Retention Requirements.....	3-8

Section 4. Participant Accrual

4.1	Study Accrual Plan and Site-Specific Accrual Targets.....	4-1
4.2	Screening and Enrollment	4-2
	4.2.1 Definition of Screening.....	4-2
	4.2.2 Eligibility Determination	4-2
	4.2.3 Definition of Enrollment	4-5
	4.2.4 Screening and Enrollment Timeframe.....	4-5
	4.2.5 Screening and Enrollment Logs	4-6
	4.2.6 Assignment of Participant ID Numbers	4-6
	4.2.7 Screening HIV Testing.....	4-7
	4.2.8 Random Assignment	4-7
	4.2.8.1 Overview	4-7
	4.2.8.2 Participant Specific Procedures.....	4-15
	4.2.8.2.1 In-Clinic Randomization Procedures.....	4-15
	4.2.8.2.2 In-Pharmacy Randomization Procedures.....	4-17
	4.2.8.3 Replacement Participants.....	4-17
	4.2.8.3.1 Specific Procedures for Replacement Participants	4-17

Section 5. Informed Consent

5.1	Overview of Informed Consent for Screening and Enrollment.....	5-1
	5.1.1 Deliver Required Information in an Understandable Manner	5-2
	5.1.2 Obtain Consent in a Setting Free of Coercion.....	5-2
	5.1.3 Confirm Participant Comprehension.....	5-2
	5.1.4 Document the Process	5-3
5.2	Informed Consent for Specimen Storage	5-4
5.3	Informed Consent SOP.....	5-4

MTN-007 Study Specific Procedures Manual

Table of Contents

5.4	Storage of Consent Forms	5-5
5.5	Informed Consent Support Materials	5-5

Section 6. Participant Follow-up

6.1	Study Follow-up Plan	6-1
6.2	Types of Follow-up Visits	6-1
6.3	Follow-up Visit Scheduling.....	6-1
6.3.1	Target Visit Dates.....	6-1
6.3.2	Visit Windows.....	6-2
6.3.3	Visits Conducted Over Multiple Days: “Split Visits”	6-2
6.3.4	Missed Visits	6-2
6.4	Follow-up Visit Procedures.....	6-2
6.5	Follow-up Visit Locations.....	6-4
6.6	Study Product Supply/Dispensing During Follow-up	6-4
6.7	HIV Testing During Follow Up	6-4
6.8	Modified Follow Up Procedures	6-4
6.8.1	Participants Who Become Infected with HIV	6-4
6.8.2	Participants Who Become Pregnant	6-5
6.8.3	Participants Who Voluntarily Discontinue Study Product	6-5
6.8.4	Participants Discontinued From Study Product by the Site Investigator	6-6
6.9	Participant Transfer	6-6
6.10	Study Exit Considerations	6-6
6.10.1	Final Study Contacts	6-6
6.10.2	HIV Counseling and Testing	6-7
6.10.3	Product Hold/Discontinuation	6-7
6.10.4	AE Management and Documentation	6-7
6.10.5	Referral to Non-Study Service Providers	6-8
6.10.6	Post Study Contacts.....	6-8

Section 7. Visit Checklists

7.1	Use of Visit Checklists	7-1
7.2	Sequence of Procedures.....	7-2

Section 8. Participant Retention

8.1	Retention Definitions	8-1
8.2	Retention Requirements	8-1
8.3	Retention SOPs.....	8-2
8.4	Obtaining and Updating Locator Information	8-2
8.5	Retention Tips	8-3

Section 9. Study Product Considerations for Non-Pharmacy Staff

9.1	Responsibilities and Obligations with Regard to Blinding	9-1
9.2	Study Product Regimens	9-2
9.3	Gel Use Instructions	9-3

MTN-007 Study Specific Procedures Manual

Table of Contents

9.4	Dispensing Study Products During On-Site Visits.....	9-3
9.4.1	Dispensing from the Pharmacy Directly to Participants	9-4
9.4.2	Dispensing from the Pharmacy to Clinic Staff.....	9-4
9.5	Study Product Returns.....	9-4
9.6	Study Product Retrieval.....	9-5

Section 10. Clinical Considerations

10.1	Baseline Medical and Menstrual History	10-1
10.2	Follow up Medical/Menstrual History	10-3
10.3	Pre-Existing Conditions	10-3
10.4	Concomitant Medications.....	10-3
10.5	Physical Exams.....	10-5
10.6	Rectal Exams.....	10-5
10.6.1	Anorectal Visual Inspection	10-6
10.6.2	Digital Rectal Exam	10-6
10.6.3	Specimen Collection.....	10-6
10.6.4	Sigmoidoscopy	10-7
10.6.5	Anoscopy.....	10-7

Section 11. Adverse Event Reporting and Safety Monitoring

11.1	Definitions.....	11-1
11.1.1	Adverse Event (AE)	11-1
11.1.2	Serious Adverse Events (SAEs).....	11-2
11.1.3	Expedited Adverse Events (EAEs).....	11-2
11.2	Adverse Event Terminology	11-3
11.3	Adverse Event Severity	11-4
11.3.1	Assigning Severity Grade for Laboratory Assays on Case Report Forms	11-5
11.4	Adverse Event Relationship Assessment	11-6
11.5	Follow up Information on Adverse Event.....	11-6
11.6	Outcome of Adverse Events, Review of AE Reports, and Study Physician Assessment and Signature.....	11-7
11.7	Reporting Recurrent Adverse Events	11-8
11.8	Social Harms	11-8
11.9	Safety Distributions from DAIDS	11-9
11.10	Safety Monitoring, Review and Oversight.....	11-10
11.11	MTN-007 Protocol Safety Review Team (PSRT).....	11-10
11.11.1	Roles and Responsibilities of the PSRT	11-10
11.11.2	PSRT Composition.....	11-11
11.11.3	Routine Safety Data Summary Reports: Content, Format and Frequency	11-12
11.11.4	PSRT Communication.....	11-12

Section 12. Laboratory Considerations

12.1	Overview and General Guidance.....	12-1
12.2	Specimen Labeling	12-4
12.3	Procedures for Specimens that can not be Evaluated	12-4

MTN-007 Study Specific Procedures Manual

Table of Contents

12.4	Use of LDMS.....	12-4
12.5	Urine Testing for Urinalysis, Pregnancy, Chlamydia, and Gonorrhea	12-7
	12.5.1 Specimen Collection.....	12-7
	12.5.2 Dipstick Urinalysis	12-8
	12.5.3 Pregnancy Testing	12-8
	12.5.4 Chlamydia and Gonorrhea Testing.....	12-8
12.6	Blood Testing.....	12-8
	12.6.1 Specimen Collection and Initial Processing	12-9
	12.6.2 HIV Testing	12-9
	12.6.3 Syphilis Testing.....	12-9
	12.6.4 Hepatitis B Surface Antigen and HSV-1 and HSV-2 IgG Serology	12-10
	12.6.5 HSV Serology.....	12-10
	12.6.6 Hematology Testing	12-10
	12.6.7 Liver and Renal Function Testing	12-10
	12.6.8 Plasma Archive.....	12-10
12.7	Testing of Rectal Specimens	12-11
	12.7.1 Rectal NAAT for Chlamydia and Gonorrhea.....	12-12
	12.7.2 Rectal Mircoflora.....	12-12
	12.7.3 Rectal Sponge for Cytokines	12-13
	12.7.4 Fecal Calprotectin.....	12-13
	12.7.5 Epithelial Sloughing	12-13
	12.7.6 Biopsy for Histology	12-14
	12.7.7 Biopsies for Cytokine RT PCR	12-14
	12.7.8 Biopsies for Mucosal T Cell Phenotyping.....	12-14
	12.7.9 Mucosal Gene Expression Array.....	12-15

Section 13. Data Collection

13.1	DataFax Overview.....	13-1
13.2	DataFax Form Completion.....	13-2
	13.2.1 General Guidelines.....	13-2
	13.2.2 How to Mark Response Boxes	13-3
	13.2.3 How to Record Numbers.....	13-3
	13.2.4 How to Record Dates	13-4
	13.2.5 How to Record Time	13-4
	13.2.6 Data Corrections and Additions	13-5
	13.2.7 How to Handle Missing and Unknown Data.....	13-6
13.3	MTN-007 Study-Specific Data Collection Information.....	13-7
	13.3.1 Participant ID numbers (PTIDs).....	13-7
	13.3.2 Study Visit Timing	13-7
	13.3.3 Visit Codes and Page Numbers	13-10
	13.3.4 Staff Initials/Date	13-11
	13.3.5 Case Report Form Completion Schedule	13-11
	13.3.6 Site Review of DataFax Forms	13-14
	13.3.7 Faxing DataFax Forms	13-14
	13.3.8 Non-DataFax Forms	13-15
13.4	Form Supply and Storage.....	13-15
	13.4.1 Form and Specimen Label Supply	13-15
	13.4.2 Form Storage	13-15

MTN-007 Study Specific Procedures Manual

Table of Contents

13.5	Completing Interviewer-administered Forms.....	13-16
13.6	Form Completion Instructions.....	13-18
13.7	Case Report Forms	13-19

Section 14. Data Communiqués

Section 15. Study Reporting Plan

Section 16. Behavioral Measures: Web-based Questionnaires and Phone Reporting System

16.1	General Computer Use	16-1
16.1.1	Using a Mouse with a Laptop Computer.....	16-2
16.2	Administering Behavioral Measures	16-3
16.2.1	Administering the Baseline Behavioral Questionnaire (Enrollment Visit)	16-3
16.2.2	Administering the Adherence Questionnaire using PRS (Treatment 2 Visit) .	16-4
16.2.3	Administering the Product Acceptability Questionnaire (Final Clinic Visit) .	16-6
16.3	Troubleshooting and Contact Information	16-7